ILD Learning Center Content Directory

Recommended Dosing Strategy For Nerandomilast and Key Adverse Effects To Watch For

December 2025

03:42 m

Med Review

In this medication review, Corinne Young, Pulmonary Nurse Practitioner and President of the Association of Pulmonary Advanced Practice Providers (APAPP), provides a clear overview of nerandomilast, a newly approved therapy for idiopathic pulmonary fibrosis (IPF). Corinne explains recommended dosing strategies—including 18 mg twice daily as the target dose—along with when to use alternative dosing in combination with pirfenidone or nintedanib, and important considerations for patients taking CYP3A inhibitors. She also reviews the key adverse effects clinicians should monitor, including diarrhea, GI symptoms, mood changes, fatigue, dizziness, headache, and potential allergic reactions. This concise breakdown helps clinicians understand how to dose nerandomilast safely, manage side effects, and optimize treatment for patients with IPF. #IPF #IdiopathicPulmonaryFibrosis #PulmonaryCare #Nerandomilast #IPFTreatment #PulmonaryFibrosis #InterstitialLungDisease #ILD #APPeducation #PulmonaryAPP

ILD & PH-ILD at the Rheum–Pulm Crossroads

November 2025

22:52 m

Podcasts

Join host Amanda Mixon, President of RhAPP, for a special episode recorded live at the 6th Annual RhAPP Conference. In this conversation, Amanda is joined by Jessica Glennie, CNP, from the Cleveland Clinic, to explore the complex intersection of rheumatology and pulmonology, focusing on Interstitial Lung Disease (ILD) and Pulmonary Hypertension in ILD (PH-ILD). Together, they unpack how early recognition, multidisciplinary collaboration, and evidence-based management can improve outcomes for patients with connective tissue disease–related pulmonary complications. Tune in for expert insights, practical diagnostic tips, and highlights from one of the most engaging sessions of the RhAPP National Conference.

Evolving IPF Care: The Significance of Nerandomilast’s FDA Approval

October 2025

25:20 m

Podcasts

In this special crossover episode, host Amanda Mixon, PA-C, President of RhAPP, sits down with Corinne Young, FNP-C, founder and President of the Association of Pulmonary Advanced Practice Providers (APAPP), to discuss one of the most exciting developments in interstitial lung disease: the FDA approval of nerandomilast for idiopathic pulmonary fibrosis (IPF). This breakthrough marks the first new IPF therapy in more than a decade and introduces a novel PDE4B mechanism of action designed to reduce fibrosis and improve lung function. Together, Amanda and Corrine unpack the clinical data behind nerandomilast, key findings from the FIBRONEER-IPF trial, and how its safety profile—particularly reduced GI side effects—may reshape treatment pathways and patient quality of life. The conversation also highlights the overlap between rheumatology and pulmonology in managing fibrotic lung diseases and the importance of interdisciplinary collaboration as additional indications for progressive pulmonary fibrosis (PPF) are anticipated. #Rheumatology #Pulmonology #InterstitialLungDisease #IPF #Nerandomilast #Fibrosis #AdvancedPracticeProviders #APPs #FDAApproval #ClinicalUpdates

What Were The Key Findings From the FIBRONEER-IPF Study?

October 2025

03:51 m

FAQ

In this FAQ video, Corinne Young, FNP-C, founder and president of the Association of Pulmonary Advanced Practice Providers (APAPP), breaks down the pivotal FIBRONEER-IPF Phase 3 trial evaluating nerandomilast, a novel oral PDE4B inhibitor for patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled study assessed nerandomilast both as monotherapy and in combination with existing antifibrotic therapies such as pirfenidone and nintedanib. Over 52 weeks, investigators observed that nerandomilast slowed lung function decline (FVC), reduced exacerbations and hospitalizations, and demonstrated a safety profile comparable to placebo, with notably fewer gastrointestinal side effects than traditional antifibrotics. These findings mark an exciting advancement in IPF management, offering clinicians a new therapeutic option that may improve both tolerance and long-term outcomes. #IPF #Nerandomilast #FIBRONEERIPF #Pulmonology #AntifibroticTherapy #PDE4B #InterstitialLungDisease #AdvancedPracticeProviders #APPs #ClinicalTrials #FDAApproval

Emerging Therapies in ILD

October 2025

07:37 m

Webcast

In this presentation, Corinne Young reviews the latest advances in therapies for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), highlighting the promising results of nerandomilast, a phosphodiesterase-4B inhibitor with both antifibrotic and immunomodulatory effects. Phase 3 trials (FIBRONEER-IPF and FIBRONEER-ILD) demonstrated that twice-daily nerandomilast slowed lung function decline and improved outcomes across patient populations, including those with autoimmune-related disease. The discussion also covers the drug’s safety profile—showing fewer gastrointestinal side effects compared to existing antifibrotic agents—and emerging treatments such as inhaled treprostinil, which is being studied for pulmonary fibrosis beyond pulmonary hypertension. With multiple new agents and combination therapies on the horizon, these developments represent meaningful progress in the treatment and management of fibrotic lung disease.

Antifibrotic Therapy

October 2025

06:40 m

Webcast

In this session, Corinne Young reviews the evolution of antifibrotic therapies for interstitial lung disease, beginning with the 2015 U.S. approval of pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF). Pirfenidone works by targeting TGF-β and TNF-α to slow fibroblast proliferation and collagen synthesis, though patients often experience gastrointestinal side effects and fatigue. The discussion also covers nintedanib (Ofev), a tyrosine kinase inhibitor that blocks multiple growth factor pathways (VEGF, FGF, PDGF) and is now approved for both IPF and other progressive fibrotic lung diseases. Clinical trials such as CAPACITY, ASCEND, INPULSIS, and INBUILD demonstrated that these antifibrotics significantly slow the rate of lung function decline and disease progression. The talk concludes by emphasizing careful side-effect management, liver monitoring, and appropriate patient selection to optimize outcomes with these cornerstone antifibrotic therapies.

The Rheum-Pulm Interface: Bridging Specialties in SARD-ILD

October 2025

11:21 m

Webcast

In this session, Corinne Young and Wendy Simmons highlight the importance of a multidisciplinary approach to managing interstitial lung disease (ILD) in patients with systemic autoimmune and rheumatologic disorders. Collaboration between rheumatology, pulmonology, and radiology teams is key to early recognition, diagnosis, and treatment planning—especially given the high risk of ILD-related morbidity and mortality in conditions like systemic sclerosis, rheumatoid arthritis, lupus, and Sjögren’s syndrome. The discussion reviews ACR screening guidelines, emphasizing the role of high-resolution CT imaging, pulmonary function testing, and oxygen desaturation monitoring. It also covers evidence-based first-line and escalation therapies, including mycophenolate, cyclophosphamide, and rituximab, while underscoring the need for frequent assessment, early intervention, and coordinated care to improve patient outcomes.

Understanding the Landscape of ILD: Burden, Pathophysiology, and Classification

October 2025

20:49 m

Webcast

In this presentation, pulmonary nurse practitioner Corinne Young and rheumatology physician assistant Wendy Simmons explore the complex relationship between interstitial lung disease (ILD) and connective tissue diseases (CTDs). Together, they provide a multidisciplinary perspective—highlighting how collaboration between pulmonology, rheumatology, and radiology leads to earlier diagnosis, better management, and improved outcomes. The session covers ILD classifications, common causes such as autoimmune disorders, environmental exposures, and drug toxicities, as well as diagnostic tools including high-resolution CT imaging, pulmonary function testing, and serologic assays. The speakers also discuss the importance of recognizing progressive phenotypes, understanding imaging patterns like UIP and NSIP, and tailoring therapy based on disease behavior. This session emphasizes that in ILD, time is lung—early recognition and coordinated care are essential to preserving function and extending quality of life.

IPF & PPF: Natural History, Diagnosis, and Management

October 2025

07:52 m

Webcast

In this educational session, Corinne Young breaks down the underlying mechanisms, progression, and management of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The discussion covers common genetic and environmental risk factors—including family history, smoking, and occupational exposures—and explains how chronic inflammation leads to fibrosis and loss of lung elasticity. Listeners gain a clear understanding of how progressive pulmonary fibrosis is identified through lung function tests (FVC, DLCO) and imaging changes over time. The presentation also addresses treatment strategies, highlighting when corticosteroids may be appropriate, why long-term steroid use is limited, and how newer antifibrotic and immunomodulatory therapies are improving outcomes for patients with fibrotic lung disease.

Rheumatoid Arthritis Associated ILD, End Stage Therapy, and Multidisciplinary Care

October 2025

02:31 m

Webcast

In this discussion, Corinne Young explores the complexities of managing patients with advanced interstitial lung disease, emphasizing the importance of early referral for lung transplant and cautious evaluation of unproven stem cell therapies. The conversation highlights how patients are sometimes misled into costly, non-evidence-based treatments abroad and underscores that only limited data exist for hematopoietic stem cell use in this setting. The speakers stress the critical role of multidisciplinary collaboration among pulmonology, rheumatology, gastroenterology, and cardiology teams, along with early conversations about palliative care and quality-of-life goals. With new therapies emerging, the focus remains on preserving lung function, aligning treatment with patient priorities, and ensuring compassionate, coordinated care for those facing progressive disease.